The revenue for NKX-19 is expected to reach an annual total of $105 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

NKX-19 Overview

NKX-019 is under development for the treatment of B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large b-cell lymphoma and acute lymphoblastic leukemia. The therapy constitutes of genetically manipulated allogeneic NK cells which express a chimeric antigen receptor targeting tumor cells expressing B lymphocyte antigen CD19, transduced by gamma-retrovirus. It is administered intravenously.

Nkarta Overview

Nkarta a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK), cell therapies to treat cancer. The company product pipeline includes NKX101, NKX019, CD70 AND NK+T. Nkarta lead products candidate NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells and NKX019 to treat a variety of B-cell malignancies by targeting the clinically and commercially validated CD19 antigen that is found in different B-cell malignancies. The company also carries out the research and development and clinical trials. Nkarta headquartered in South San Francisco, California, the US.

The operating loss of the company was US$119 million in FY2022, compared to an operating loss of US$86.4 million in FY2021. The net loss of the company was US$113.8 million in FY2022, compared to a net loss of US$86.1 million in FY2021.

For a complete picture of NKX-19’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.